Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Gilead Sciences (NQ: GILD)
75.20 USD  -0.41 (-0.54%)
Streaming Delayed Price  /  Updated: 7:28 AM EDT, Jul 9, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 9,976
Open 75.61
Bid (Size) 75.13 (3)
Ask (Size) 75.50 (4)
Prev. Close 75.61
Today's Range 75.20 - 75.92
52wk Range 60.89 - 85.97
Shares Outstanding 1,300,260,832
Dividend Yield 2.97%
Performance
YTD
+15.28%
+15.28%
1 Month
-2.30%
-2.30%
3 Month
+0.28%
+0.28%
6 Month
+14.29%
+14.29%
1 Year
+11.00%
+11.00%
Top News
More News
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and... Read More
from Business Wire News Releases
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir... Read More
from Business Wire News Releases
More News
Read More
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
from Business Wire News Releases
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
from Business Wire News Releases
New Day, New Sentiment: Travel And Tech Stocks On Defense After Monday's Big Gains
category Raphael Bostic , Economics , Investor Sentiment , and 30 more.
from Benzinga
Gilead Aims To Expand Remdesivir Use By Testing Inhaled Coronavirus Drug
from Investor's Business Daily
Here’s How The Coronavirus Pandemic Became an Investing Opportunity For Me
category Market News , ABT , SPY , and 4 more.
from Motley Fool
Gilead Sciences Sees RS Rating Improve To 73
from Investor's Business Daily
Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis
from Investor's Business Daily
Here's the Surprising Coronavirus Stock You'll Really Want to Own
category ALT , AFTP/F , SHOP , and 11 more.
from Motley Fool
Regeneron Nears Buy Point As Drugmaker Begins Late-Stage Covid-19 Tests
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.